ABSTRACT
INTRODUCTION
Leishmaniasis is a vector-borne disease and considered as one of the world's most neglected diseases. The annual global incidence of leishmaniasis is approximately 12 million cases. 1 Leishmaniasis is endemic in 88 countries with more than 350 million peoples are at risk. 2, 3 The number of cases reported globally has increased over the past 10 years due to the increase in anti-leishmanial drug resistance and lack of adequate vector or reservoir control tools. 4 Antimonial compounds are the first line drugs and drug of choice for the treatment of leshmaniasis but the emergence of drug resistance against these drugs is an emerging problem and spread of drug resistance strains of Leishmania is an alarming feature. Newer drugs like Miltifosine and Amphoterisin B is approved for the treatment of leshmaniasis are highly toxic and above all are very expensive. Thus, the control of leishmaniasis has become a costly affair due to the high cost of alternative drugs. For the control of leishmaniasis, there is a need to discover a novel compound which should not only be less toxic but also cost effective. During the last few years, researchers have focused their interest on the discovery of new anti-leishmanSubmission Date: 18-09-2017; Revision Date: 08-11-2017; Accepted Date: 21-11-2017 ials by the isolation of bioactive molecules from plants, by semi synthetic and synthetic approach 5, 6 and some of synthetic molecules undergo clinical trials which have shown efficacy against Leishmania parasite. 7, 8, 9 Chalcones and flavone analogues are the integral component of many pharmacological active compounds like antiprotozoal, anti-inflammatory, immunomodulatory, nitric oxide inhibition, anticancer. 10, 11 The molecular basis of the anti-leishmanial action is still not well established. 12 The Pteridine reductase (PTR1) is a member of oxido-reductase family, which has become an attractive target for the development of novel anti-leishmanial agents. Pteridine reductase is a flavoprotein, which is unique in leishmania and plays vital role in the growth of the leishmania via generation of intermediate which is required for the synthesis of DNA precursors. 13 The enzyme PTR1 is predominantly involved in reduction of biopterin to dihydrobiopterin and tetrahydrobiopterin but it is also capable to reduce dihydrofolate to tetrahydrofolate. Hence, a combined strategy to target both PTR1 and Dihydrofolate reductase (DHFR) will be more effective to stop parasitic growth and survival. A number of other compounds have been screened against PTR1 in L. donovani.
14 Several natural flavonoids were found to be inhibiting both DHFR and PTR1. 15 So, the present strategy reflects the study of new flavanone analogues as promising anti-leishmanial agents targeting Pteridine reductase coupled with DHFR. This indicates that some novel flavanone analogues as an inhibitor are essentially required that targets both the enzymes simultaneously.
Researchers recently identified several types of flavonoids as antiprotozoal principles of plant extracts, 16, 17, 18 but a comprehensive study of their structure-activity relationships (SARs) has not been conducted so far. Therefore, it was our fine interest to assess the in vitro leishmanicidal activities of a large 3-substituted flavanone analogues library, draw SARs, and determine their anti-leishmanial activity without significant toxicity in mammalian cells.
MATERIALS AND METHODS

Chemicals
All the chemicals and solvents used were of AR-grade and LR-grade and were obtained from Sigma-Aldrich, Sisco Research Laboratories, Qualigens, Rankem, S.D. Fine, Hi-Media and Merck.
Synthesis of 3-methyl chalcone
To a solution of 0.01 mole of substituted 2'-hydroxypropiophenones in 10 ml of 40% KOH and 20 ml of ethyl alcohol, 0.01mole of substituted benzaldehyde was added and mixture was stirred for 48-72 h. The coloured solution was poured into crushed ice and acidified with 1N HCl at 24-26 0 C. The precipitate so obtained was washed with cold water, filtered, dried and recrystallized with absolute alcohol.
Synthesis of 3-methyl flavone
To a solution of 0.01 mole of chalcone in 50 ml of dimethyl sulphoxide (DMSO) taken in 100 ml round bottom flask fitted with reflux condenser, 15-20 granules of iodine was added. The reaction mixture was refluxed for 3-4 h and kept overnight. The precipitate was neutralized with sodium thiosulphate to remove unreacted I 2 washed with water, fitted, dried and recrystallized with absolute alcohol.
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Synthesis of 3-methyl flavanone
To 0.01 moles of 3-methyl flavone in 100ml round bottom, the equimolar amount of NaBH4 and 10-15 ml of methanol in the presence of AlCl 3 was added and mixture was refluxed for 2-3 h. The resulting solution was cooled to room temperature followed by the addition of ice cold water. The solid was separated by filtration, washed with cold water and recrystallized from ethanol. The experiments suggest that the present reductive system initially reduces the conjugated double bond see Table 1 .
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Synthesis of 2'-hydroxy chalcones
To a solution of 0.01 mole of substituted 2'-hydroxyacetophenones in 10 ml of 40% KOH and 20 ml of ethyl alcohol, 0.01mole of substituted benzaldehyde was added and mixture was stirred for 48-72 h. Completion of the reaction was monitored on TLC (20% Ethyl acetate in toluene). The coloured solution was poured into crushed ice and acidified with 1N HCl at 24-26 0 C. The precipitate so obtained was washed with cold water, filtered, dried and recrystallized with absolute alcohol. To a suspension of 0.01ml of chalcone, 50 ml of ethanol was added l0 ml of 20% aqueous sodium hydroxide with stirring, followed by the careful addition of I5 ml of 30% hydrogen peroxide over a period of 0.5-1 h. The reaction mixture was stirred for 3-5 h at 30°C and completion of the reaction was monitored on TLC (20% Ethyl acetate in toluene). After reaction completion, the mixture was poured into crushed ice containing 5 N HCl. The precipitate was filtered, washed, dried and recrystallized from ethyl acetate.
Synthesis of 3-hydroxyflavones
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Synthesis of 3-hydroxyflavanone analogues
To a solution of 0.01 mole of 3-hydroxyflavone, 10-15 ml of methanol and 0.01 mole of NaBH 4 was added and the mixture was refluxed for 3-4 h in the presence of cobalt(II) phthalocyanine to yield 3-hydroxyflavanone analogues.
Anti-leishmanial Activity
Chemicals
Parasite stock culture: Axenic culture of L. donovani (LdMIPL-1) was maintained at 25°C in RPMI 1640 (Himedia, India) medium supplemented with 10% heat inactivated Fetal Bovine Serum (FBS) (Himedia, Mumbai, India), streptomycin (150 μg/mL), penicillin G (100 μg/mL) and gentamycin (150 μg/mL) at pH 7.2
Anti-leishmanial assay
For antileishmanial activity, pro-mastigotes of L. donovani were sub-cultured in Schneider's Insect Medium (Himedia, Mumbai, India) supplemented with 10% heat inactivated FBS, streptomycin (150 μg/mL), penicillin G (100 μg/mL) and gentamycin (150 μg/mL). The antileishmanial screening was performed in 96-well flat bottom tissue culture plates (Corning Life Science, Corning USA) 100 microliters of cell suspension containing 2 × 10 6 to 3 × 10 6 cells/mL was poured in each well of the plate. Four different concentrations of the methanolic extracts i.e. 100, 250, 350 and 500 μg/ mL, dissolved in dimethyl sulfoxide (<0.025% v/v) and added to the culture. The plates were then incubated at 25°C for 24 h. Amphotericin B and sodium stibugluconate were used as positive controls and cell suspension with 0.025% DMSO was used as a negative control. Inhibition of the promastigotes was assessed by measuring the cleavage of 10 mg/mL of MTT [3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide]. 23, 24, 25 The absorbance was measured using an ELISA plate reader (BioTek, USA) at 595 nm. Percent growth inhibition was calculated by the following formula: Library of 20 substituted flavanone analogues were prepared by using chemdraw ultra 11.0. All ligands were prepared through Auto Dock Tools. The 3D crystal structure was obtained from Protein Data Bank (PDB code: 2XOX). 26 The 3D structures of PTR1, (from 2XOX), was used for virtual screening. 27 Docking parameters were set to default values on the basis of Lamarckian genetic algorithm principle. 28 
RESULTS
Chemistry
Synthesis of 3-hydroxy and 3-methylflavanone analogoues involve 3 steps (See Figure 1A and 1B). Spectral Analysis of 1a-10a (3.1.1.1 to 3.1.1.10) and 1b-10b (3.1.1.11 to 3.1. Pale yellow solid, physical data is summarized in Table 2 . IR spectra (KBr cm 
2-(4-chlorophenyl)-2,3,dihydro-3-methylchromen-4-one(2a)
Light yellow solid, the physical data is summarized in Table 2 . IR Spectra (KBr cm Dark brown solid, physical data is summarized in Table  2 . IR Spectra (KBr cm 
2-(benzo[d][1,3]dioxal-6-yl)-2,3-dihydro-3-methylchromene-4-one(5a)
Yellow solid, physical data is summarized in Table 2 . IR Spectra (KBr cm 
2-(2-bromophenyl)-2,3,dihydro-3-methylchromen-4-one(6a)
Light yellow solid, the physical data is summarized in Table 2 . 8a: IR spectra (KBr cm Yellow-white solid, physical data is summarized in Table 2 . IR spectra (KBr cm Yellow solid, physical data is summarized in Table 2 . IR spectra (KBr, cm Yellow-brown solid, physical data is summarized in Table 3 
2-(4-(chlorophenyl)-2,3-dihydro-3-hydroxychromen-4-one (2b)
Yellow-white solid, physical data is summarized in 
2-(furan-2-yl)-2,3-dihydro-3-hydroxychromen-4-one (3b)
Yellow solid, physical data is summarized in Table 3 
2-(4-(dimethylamino)phenyl-2,3-dihydro-3-hydroxy-7-methoxychromen-4-one (4b)
Yellow-brown, physical data is summarized in Table 3 . (4-(chlorophenyl)-2,3-dihydro-3-hydroxy- 
7-methoxychromen-4-one (5b)
Yellow-brown, physical data is summarized in Table 3 
2-(furan-2-yl)-2,3-dihydro-3-hydroxy-7-methoxychromen-4-one (6b)
Yellow-brown, physical data is summarized in Table 3 . 
2-(4-(dimethylamino)phenyl-2,3-dihydro-3-hydroxy-6-methylchromen-4-one (7b)
Yellow-brown, physical data is summarized in Table 3 (chlorophenyl)-2,3-dihydro-3-hydroxy-7-methylchromen-4-one (8b) Yellow solid, physical data is summarized in Table 3 
2-(4-
2-(furan-2-yl)-2,3-dihydro-3-hydroxy-6-methylchromen-4-one (9b)
2,3-dihydro-3-hydroxy-2-(4-nitrophenyl)chromen-4-one (10b)
Yellow-brown, physical data is summarized in Table 3 . 2H, m ,2',6'-H ), 7.39 (1H, dd, 7-H,J=7 .76 Hz), 6 .97 (1H, d, 6-H, J= 8.23 Hz ), 6.74 (1H, d, 8-H analogues (1a-10a) Physicochemical characterizations of 3-methylflavanone analogues are listed in Table 2 . 3-hydroxyflavanone analogues (1b-10b) Physicochemical characterization of 3-hydroxyflavanone analogues are listed in Table 3 .
Physicochemical characterization of 3-methylflavanone
Physicochemical characterization of
Anti-leishmanial Activity
The anti-leishmanial activities of synthesized compounds were screened against promastigotes of L.donovani. Amphotericin B and Sodium Stibugluconate were used as standard drugs and exhibited 100 % inhibition. The results are presented in Table 4 .
Docking Study
All the twenty compounds were docked into the active site of the PTR1 and the estimated free binding energy were presented in Table 5 and the interaction of most promising test compounds with receptors were illustrated in Figure 2 A and 2 B respectively.
DISCUSSION
All the selected 20 compounds were investigated for their activities against axenic L. donovani prmastigotes, grown in simple media have been used as test parasite to screen potential antileishmanial agents and the simplicity of this system accounts for its wide popularity, and the results were expressed as % inhibition illustrated in Table 4 with few exceptions, all 3-methyl and 3-hdroxy flavanone showed significant antileishmanial activity. The test compounds such as 4b (95%), 10b (93%), 5b (92%), 6b (91%), and 3a (90%) being the most potent. Their % inhibitions were almost comparable to that of Amphotericin B and Sodium Stibugluconate the antileishmanial drug used in the clinic. Starting with the flavanone, the insertion of a single OH group at the benzo-γ-chromone (at-3-position) portion of the flavone structure have a notable influence, but insertion of one more OH / OCH 3 on ring A and B functions significantly enhanced the leishmanicidal potential. Particularly important positions were C-5, C-7 on ring A. Hydroxylation on ring B had some impact on the activity, but a clear SAR could not be observed. Further, compounds such as 9b (87%), 4a (84%), 5a (82%), 9a (81%), 3b (81%), 7a (80%) and 1b (80%) have shown appreciable leishmanicidal activity as compared with that of the standard drugs, as most of the test compounds were in conjugation with hydroxyl or electron donating groups except nitro group. However, compounds such as 8b (72%), 8a (71%), 10a (68%) and 2b (62%) exhibited moderate activity against promastigates of L.donovani, as these compounds were having either mild electron withdrawing group or without electronic effect on main nucleus. The presence of strong electron withdrawing group on the entire structure significantly reduced the leishmanicidal activity as observed in compounds, such as 1a (12%) 2a (15%), 6a (18%) see Table 1 .
Based on the information obtained, it is difficult to decipher empirical SARs among the test compounds investigated in the current study. It is quite noteworthy in the finding that majority of leishmanicidal compounds have a typical 3-hydroxy flavanone structure with one or more substitution by hydroxyl or methoxy groups or electron donating group(s). Furthermore, drug receptor interaction was carried out to validate our findings. The ligands were ranked according to docking score /estimated free energy of binding. The free energy of binding of ligands was in the range between -3.15 to -7.84.Kcal/mole. Top ranked compound (4b) and (10b) with -7.84 and-7.77 Kcal /mole free energy of binding, respectively, were in correlation with wet lab experiments. The protein ligand analysis also has shown its strong interactions with target protein and had five hydrogen bond interaction in (4b) and four hydrogen bond interaction in (10b). The residues involved in hydrogen bond interaction were An in-vitro promising anti-leishmanial activity of the compounds demands further in-vivo and clinical studies and these compounds might find an important place in the new array of molecules targeting PTR1 dependent biological functions as anti-leishmanial agents. However, there are some limitations of using promastigotes for in vitro anti-leishmanial study; the metabolism and ecology of promastigote differ so widely from those of amastigote that screening data obtained from in vitro test with promastigote have very little value in animals. 29, 30 Another condition which reduces leishmanicidal action in vitro is lower temperature (24°C) at which the culture normally grows, as opposed to the in vivo temperature of 37°C. The promastigote in culture at 37°C will survive but not multiply. Further, the promastigote culture represents an artificial situation and is not always showing a significant value for drug screening.
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CONCLUSION
This study reports on the in vitro anti-leishmanial activity of a number of flavanone analogues synthesized from 2'-hydroxypropiohenones, 2'-hydroxyacetophenone, and substituted benzaldehyde. The study was prompted by the need of novel, efficacious and cost-effective medicines against this parasitic disease. After elucidating the chemical structure of the newly synthesized flavanone analogues, they were evaluated for their potential leishmanicidal activity against cultured L. (L.) donovani promastigotes. These experiments revealed promising anti-leishmanial activity of particularly compound 10b, which also showed the best docking into the active site of pteridine reductase.
SUMMARY
Leishmaniasis is a vector-borne disease and considered as one of the world's most neglected diseases, is endemic in 88 countries with more than 350 million people at risk The World Health Organization emphasized that plants used in traditional medicine and their synthetic analogues should primarily be investigated against leishmaniasis. The proposed work of in silico study exhibits the high degree of statistical significance and good predictive ability. The information obtained from this study could provide vital information for future development of potent anti-leishmanial agents as pteridine reductase inhibitors. A series of flavanones with various structural features has been synthesized and evaluated for in vitro anti-leishmanial activity; the potent compounds should be further evaluated in vivo anti-leishmanial efficacy in L. donovani / hamster model as future target. Herein, we have been able to document a comprehensive assessment of anti-leishmanial activity and structure-activity relationship analyses of promising flavanone analogues. 
